YOLFTbeta
Elicio Therapeutics Inc.

Elicio Therapeutics Inc.

ELTX · NASDAQ · Healthcare / Biotechnology

1.50USD-0.06 (-3.85%)

Price History

Full chart

Market Stats

Previous Close1.56
Open1.57
Day Range1.48 – 1.60
52-Week Range1.71 – 16.00
Volume327.02K
Market Cap49.41M
P/E (TTM)0.00
Forward P/E0.00
EPS-2.15
Dividend Yield0.00%
Beta1.86
50-Day Avg2.72
200-Day Avg7.60

About

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Robert T. Connelly
  • Employees33
  • Headquarters451 D Street, Boston, MA, United States, 02210, USA
  • Websitehttps://elicio.com

Leadership

  • Mr. Robert T. ConnellyCEO, President & Director · b. 1960
  • Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D.Founder & Independent Director · b. 1947
  • Dr. Preetam Shah M.B.A., Ph.D.Chief Strategy & Financial Officer and Treasurer · b. 1973
  • Dr. Christopher M. Haqq M.D., Ph.D.Executive VP, Head of Research & Development and Chief Medical Officer · b. 1966
  • Dr. Darrell J. Irvine Ph.D.Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board
  • Mr. Marc J. Wolfgang M.S.Chief Technology Officer
  • Dr. Peter DeMuth Ph.D.Chief Scientific Officer · b. 1987
  • Ms. Megan C. FiloonGeneral Counsel, Secretary & Compliance Officer
  • Ms. Esther WelkowskySenior Vice President of Clinical Development
  • Ms. Joy SeymourSenior VP & Head of Regulatory Affairs

Financials

Income Statement

Currency: USD2012-12-312013-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue7.30M6.58M4.03M1.49M2.88M28.31M0000
Growth (%)--9.82%-38.78%-63.09%+93.68%+883.06%-100.00%---
Cost of Revenue3.67M3.17M380.00K1.14M1.82M1.23M1.06M1.17M1.18M1.13M
Gross Profit3.62M3.41M3.65M351.00K1.06M27.08M-1.06M-1.17M-1.18M-1.13M
Gross Margin49.66%51.78%90.57%23.60%36.88%95.64%----
Operating Expense4.04M3.81M17.99M38.94M56.34M66.39M22.68M34.58M43.81M36.59M
Operating Income-419.22K-397.80K-14.34M-38.59M-55.27M-39.31M-23.73M-35.74M-44.99M-37.71M
Operating Margin-5.74%-6.04%-355.97%-2595.23%-1919.20%-138.84%----
EBITDA1.96M62.54K-14.34M-40.16M-70.63M-51.92M-23.55M-32.97M-50.27M-37.31M
EBITDA Margin26.92%0.95%-355.92%-2700.87%-2452.53%-183.40%----
Net Income307.30K632.24K-20.02M-40.66M-80.11M-26.40M-28.21M-35.20M-51.90M-39.57M
Net Income Margin4.21%9.61%-497.02%-2734.23%-2781.49%-93.25%----
R&D-196.01K9.15M29.79M38.88M48.61M17.05M22.68M33.66M24.90M
R&D as % of Total Revenue-2.98%227.13%2003.16%1349.97%171.68%----
Interest Expense307.45K300.43K--8.85M876.44K3.60M1.06M455.00K1.13M
Interest Expense % of Total Revenue4.21%4.57%--307.15%3.10%----

Balance Sheet

Currency: USD2012-12-312013-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets11.03M11.06M26.63M11.89M47.35M96.51M22.66M27.15M28.18M25.86M
Total Liabilities6.79M6.60M7.72M30.47M137.80M15.01M13.75M15.77M39.49M24.23M
Total Equity1.71M2.34M18.91M-18.59M-90.45M81.51M8.91M11.37M-11.31M1.64M
Cash1.40M2.06M25.51M5.57M34.61M88.76M7.80M12.89M17.62M18.56M
Total Debt5.44M5.32M-10.78M85.04M4.66M7.48M6.92M26.04M14.51M
Net Debt4.04M3.27M-25.51M5.21M50.44M-84.09M-316.00K-5.98M8.42M-4.05M

Cash Flow

Currency: USD2012-12-312013-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.07M1.89M-8.02M-24.59M-22.89M-23.94M-22.18M-32.69M-37.07M-36.95M
Investing Cash Flow-47.73K-67.58K--242.00K-41.00K-525.36K-654.00K-32.00K-84.00K-16.00K
Financing Cash Flow-429.23K-1.17M31.74M4.89M52.41M19.39M21.20M38.61M42.32M36.70M
Capital Expenditure47.73K17.57K0242.00K41.00K525.36K654.00K66.00K87.00K16.00K
Free Cash Flow1.02M1.87M-8.02M-24.83M-22.93M-24.46M-22.83M-32.76M-37.16M-36.97M
FCF to OCF95.52%99.07%100.00%100.98%100.18%102.19%102.95%100.20%100.23%100.04%

Earnings

Report DateMay 17, 2021Jul 13, 2021Nov 12, 2021May 17, 2022Aug 16, 2022Nov 14, 2022Mar 29, 2023May 10, 2023Aug 11, 2023Nov 9, 2023Mar 29, 2024May 15, 2024Aug 13, 2024Nov 13, 2024Mar 27, 2025May 13, 2025Aug 7, 2025Nov 13, 2025Dec 31, 2025May 11, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate-0.00--4.35-4.63-3.60-2.10---0.80-0.78-1.09-0.96-0.73-0.88-0.83-0.69-0.48-0.45-0.46-0.53-0.52
EPS Actual-15.65-0.45-5.26-4.80-3.00-3.00-2.10-1.51-2.44-1.27-1.75-1.15-0.64-1.39-1.02-0.87-0.66-0.60-0.49-0.65-0.43-
Surprise----10.34%35.21%16.67%0.00%---58.75%-124.36%-5.50%33.33%-90.41%-16.57%-4.82%4.35%-25.00%-10.11%-41.30%18.87%-
Timing-------After-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap49.41M
Enterprise Value39.68M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book6.18
EPS-2.15
Book Value0.362
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-37.74M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-774.56%
Return on Assets-77.88%
Shares Outstanding26.28M
Shares Float19.19M
Beta1.86
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 13.67
  • Strong Buy
    1
  • Buy
    1

Ownership Breakdown

Institutions
16.25%
Insiders
26.97%
Retail / Other
56.78%

Top Institutional Holders

  • Knoll Capital Management LP
    630.91K2.40%
  • Vanguard Capital Management, LLC
    518.64K1.97%
  • Balyasny Asset Management LLC
    244.81K0.93%
  • Geode Capital Management, LLC
    135.16K0.51%
  • Renaissance Technologies Corp
    121.63K0.46%
  • Marshall Wace Asset Management Ltd
    74.51K0.28%
  • Susquehanna International Group, LLP
    70.80K0.27%
  • Vanguard Fiduciary Trust Co
    69.19K0.26%
  • Northern Trust Corp
    59.73K0.23%
  • The Goldman Sachs Group Inc
    57.82K0.22%
  • 683 Capital Management LLC
    56.44K0.21%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    415.40K1.58%
  • iShares Russell 2000 ETF
    313.94K1.19%
  • Fidelity Small Cap Index
    139.90K0.53%
  • iShares Russell 2000 Growth ETF
    122.63K0.47%
  • Vifag 2002 SICAV
    119.42K0.45%
  • Vanguard Russell 2000 ETF
    75.67K0.29%
  • Lago Erie SICAV
    69.72K0.27%
  • Fidelity Extended Market Index
    62.34K0.24%
  • Abante Quant Value FI
    62.09K0.24%

Stock Splits

  • Jun 2, 20231:10